Gyrolab® is now quickly being adopted as a valuable
tool in e.g. protein therapeutic development and evaluation.
Promising progress is seen also in neighbouring application
areas.
Topics Gyrolab® has benefits that open for new
strategies and increased effectiveness in several areas of protein
analysis, including the demanding development of protein therapeutics.
Selected headlines:
•
Antibody
binding characterization
•
IgG quantification
and aggregate analysis
•
Pharmacokinetics
(PK)
•
Immunogenicity
(ADA)
•
Analysis
of host cell protein (HCP) contaminants
•
Study of
post-translational modifications
•
Biomarker
assays
The
meeting was an opportunity to:
•
Network
with Gyrolab users
•
Share
experiences and present your latest work
•
Learn
more about Gyrolab methods and applications
The
list of speakers included participants from:
- Astra
Zeneca
- GlaxoSmithKline
- MedImmune
- GE Healthcare
- HFL
- Bristol-Myers Squibb
- Stockholm University
- HFL
- Uppsala University
- Gyros
Posters
from:
- Rentschler
Biotechnologie
- Swedish National Veterinary Institute
- GlaxoSmithKline
- BAC
- Gyros
Gyros,
Gyrolab, Bioaffy and the Gyros logo are trademarks of Gyros AB.
